B

Bio-Path Holdings
D

BPTH

0.80000
USD
0.01
(1.27%)
Market Closed
Volume
151
EPS
3
Div Yield
-
P/E
-0
Market Cap
3,445,514
OverviewSignalsIdeasNews
Related Instruments
    A
    ABUS
    0.01000
    (0.28%)
    3.64000 USD
    A
    ARWR
    -2.890
    (-13.49%)
    18.540 USD
    B
    BCLI
    0.06500
    (5.75%)
    1.19500 USD
    B
    BCRX
    -0.41500
    (-5.57%)
    7.03500 USD
    C
    CANF
    -0.03000
    (-1.51%)
    1.96000 USD
    C
    CLRB
    -0.14500
    (-7.23%)
    1.86000 USD
    More
News

Title: Bio/Path Holdings

Sector: Healthcare
Industry: Biotechnology
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition forany gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.